Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing
Reexamination Certificate
2006-01-10
2006-01-10
Chen, Shin-Lin (Department: 1632)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
C435S004000, C435S006120
Reexamination Certificate
active
06984619
ABSTRACT:
Methods and pharmaceuticals for inhibiting or preventing metastasis formation in animals, including humans, having primary tumors, through the administration of phosphorothioates including their thiol and disulfide metabolites are disclosed. These compounds stimulate angiostatin levels, inhibit matrix metalloproteinases (MMPs), and stimulate manganese superoxidase dismutase (MnSOD). Phosphorothioates, of which amifostine is an example, can be administered as a combination therapy with traditional cancer therapies, including chemotherapy, radiotherapy, surgery, immunotherapy, hormone therapy and gene-therapy. Inhibition or prevention of metastasis by phosphorothioates is independent of tumor type, including adenocarcinomas and sarcomas.
REFERENCES:
patent: 5488042 (1996-01-01), Grdina
patent: 5567686 (1996-10-01), Grdina
patent: 5837696 (1998-11-01), Golub et al.
patent: 5869338 (1999-02-01), Grdina
patent: 5891856 (1999-04-01), Grdina
patent: WO 93/17689 (1993-09-01), None
patent: WO 95/07700 (1995-03-01), None
Hasegawa et al., Matrilysin-Specific Antisense Oligonucleotide Inhibits Liver Metastasis of Human Colon Cancer Cells in a Nude Mouse Model, 1998, Int. J. Cancer, vol. 76, pp. 812-816.
Milas et al.; Effect of Tumor type, Size, and Endpoint on Tumor Radioprotection by WR-2721; 1984, Int. J. Radiation Oncology Biol. Phys., vol. 10: 41-48.
Gura, T., 1997, Science, vol. 278, p. 1041-1042.
Wattenberg, L., 1997, Proceedings of the Society for Experimental Biology and Medicine, vol. 216, No. 2, p. 133-141.
Lesniak et al., 2001, Current Neurology and Neuroscience Reports, vol. 1, p. 210-216.
Grdina et al., “Prevention of spontaneous metastases formation in murine tumor models by Amifostine,”Proc. Americ. Ass. Canc. Res. Ann. Meet., No. 40, pp. 485, 2000.
Miele et al., “Enhanced metastatic ability of TNF-α-treated malignant melanoma cells is reduced by intercellular adhesion molecule-1 (ICAM-1, CD54) antisense oligonucleotides,”Expermntl. Cell Reser., 214:231-241, 1994.
Milas et al., “Protective effects of thiol compound WR-2721 against metastasis enhancement caused by cyclo-phosphamide (CY) and whole-body irradiation (WBI),”Proc. Amer. Ass. Canc. Res., 25:62, 1984.
Ulrich et al., “Influence of WR-2721 on metastatic tumor spread after irradiation,”Proc. Third. Ann. Meet. SE. Canc. Res. Ass., 1976.
Albini et al., “Inhibition of invasion, gelatinase activity, tumor take and metatasis of malignant cells by N-acetylcysteine,”Int. J. Cancer, 61:121-129, 1995.
Antras-Ferry, J. et al., “Oltipraz stimulates the transcription of the manganese superoxide dismutase gene in rat hepatocytes,”Carcinogenesis, 18:2113-2117, 1997.
Apffel, C.A. et al., “Tumor rejection in experimental animals treated with radioprotective thiols,”Cancer Res., 35:429-437, 1975.
Banner et al., “Experimental chelation therapy in chromium, lead, and boron intoxication with N-acetylcysteine and other compounds,”Toxicol. Appl. Pharmacol., 83:142-147, 1986.
Brumas et al., “Can N-acetyl-L-cysteine affect zinc metabolism when used as a paracetamol antidote?”Agents Actions, 36:278-288, 1992.
Carnes, B.A. et al., “In vivo protection by the aminothiol WR-2721 against neutron-induced carcinogenesis,”Int. J. Radiat. Biol., 61:567-576, 1992.
Das, K.C. et al., “Activation of NF-kB and elevation of MnSOD gene expression by thiol reducing agents in lung adenocarcinoma (A549) cells,”Am J. Physiol., 269:L588-L602, 1995.
De Flora et al., “Chemopreventive properties and mechanisms of N-acetylcysteine. The experimental background,”J. Cell Biochem. Suppl., 22:33-41, 1995.
De Flora et al., “Synergism between N-acetylcysteine and doxorubicin in the prevention of tumorigenicity and metastasis in murine models,”Int. J. Cancer, 67:842-848, 1996.
Fink et al., “Design and synthesis of thiol containing inhibitors of matrix metallaproteinases,”Bioorg. Med. Chem. Lett. 9:195-200, 1999.
Freskos et al., “Discovery of a novel series of selective MMP inhibitors: identification of the γ-fulfone-thiols,”Bioorg. Med. Chem. Lett., 9:943-948, 1999.
Gately et al., “Human prostate carcinoma cells express enzymatic activity that converts human plasminogen to the angiogenesis inhibitor, angiostatin,”Cancer Res., 56:4887-4890, 1996.
Gately et al., “The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin,”Proc. Natl. Acad. Aci. USA, 94:10868-10872, 1997.
Gilbert, “Redox control of enzyme activities by thiol/disulfide exchange,”In: Methods in Enzymology, Academic Press, New York, 107:330-351, 1984.
Grdina et al., “Thiol and disulfide metabolites of the radiation protector and potential chemopreventive agent WR-2721 are linked to both its anti-cytotoxic and anti-mutagenic mechanisms of action,”Carcinogenesis, 16:767-774, 1995.
Grdina et al., “Chemopreventive doses of Amifostine confer no cytoprotection to tumor nodules growing in the lungs of mice treated with cyclophosphamide,”Sem. Oncol., 26: 22-27, 1999.
Grdina et al., “Protection against late effects of radiation by s-2-(3-aminopropylamino)-ethylphosphorothioic acid,”Cancer Research, 51:4125-4130, 1991.
Grdina et al., “The radioprotector WR-2721 reduces neutron-induced mutations at the hypoxanthine-guanine phosphoribosyl transferase locus in mouse splenocytes when administered prior to or following irradiation,”Carcinogenesis, 13: 811-814, 1992.
Hirschel-Scholz et al., “Interference of WR-2721 with magnesium metabolism: mechanism of action,”Miner Electrolyte Metab., 14:114-20, 1988.
Hoffman et al., “Would fluid from venous leg ulcers degrades plasminogen and reduces plasmin generation by keratinocytes,”J. Invest Dermatol., 111:1140-1144, 1998.
Kahari et al., “Matrix metalloproteinases and their inhibitors in tumor growth and invasion,”Ann. Med., 31:34-45, 1999.
Kanclerz and Chapman, “Influence of misonidazole, sr-2508, rsu-1069 and wr-2721 spontaneous metastases in c57bl mice,”Int J Radiat Oncol Biol Phys, 14:309-316, 1988.
Kataoka et al., “Anti-mutagenic effects of amifostine: clinical implications,”Semin. Oncol., 23:53-57, 1996.
Kataoka et al., “Anti-mutagenic effects of the radioproctector WR-2721 against fission spectrum neutrons and60Co γ-rays in mice,”Int. J. Radiat. Biol., 61:387-392, 1992.
Kleiner et al., “Matrix metalloproteinases and metastasis,”Cancer Chemother. Pharmacol., 43:S42-S51, 1999.
Langeland et al., “Metal binding properties of thiols; complexes with horse liver alcohol dehydrogenase,”Comp, Biochem. Physiol Part B, 123: 155-162, 1999.
Li et al., “Overexpression of manganese superoxide dismutase in DU145 human prostate carcinoma cells has multiple effects on cell phenotype,”Prostate, 35:221-233, 1998.
Liu et al., “Repression of c-myc gene expression by the thiol and disulfide forms of the cytoprotector amifostine,”Carcinogenesis, 18:2457-2459, 1997.
Liu et al., “Transfection and expression of MnSOD cDNA decreases tumor malignancy of human oral squamous carcinoma SCC-25 cells,”Human Gene Ther., 8:585-595, 1997.
Llobert et al., “Comparative effects of repeated parenteral administration of several chelators on the distribution and excretion of cobalt,”Res. Comm. Chem. Path, Pharmacol., 60(2):255-233, 1988.
McDonnell et al., “Zinc ejection as a new rationale for the use of a cystamine and related disulfide-containing antiviral agents in the treatment of AIDS,”J. Med. Chem., 40:1969-76, 1997.
Milas et al., “Inhibition of radiation carcinogenesis in mice by S-2-(3-aminopropylamino) ethylphosphorothioic acid,”Cancer Res., 44:5567-5569, 1984.
Milas et al., “Effect of tumor type, size, and endpoint on tumor radioprotection by WR-2721,&#
Grdina David J.
Milas Luka
Arch Development Corporation
Board of Regents , The University of Texas System
Chen Shin-Lin
LandOfFree
Method for protection against tumor metastasis formation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for protection against tumor metastasis formation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for protection against tumor metastasis formation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3598914